- Home
- AEMD vs REVB Comparison
AEMD vs REVB Comparison
Compare AEMD & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEMD
- REVB
- Stock Information
- Founded
- AEMD 1984
- REVB 2020
- Country
- AEMD United States
- REVB United States
- Employees
- AEMD N/A
- REVB N/A
- Industry
- AEMD Medical/Dental Instruments
- REVB Biotechnology: Pharmaceutical Preparations
- Sector
- AEMD Health Care
- REVB Health Care
- Exchange
- AEMD Nasdaq
- REVB Nasdaq
- Market Cap
- AEMD 4.1M
- REVB 3.8M
- IPO Year
- AEMD N/A
- REVB N/A
- Fundamental
- Price
- AEMD $1.33
- REVB $2.88
- Analyst Decision
- AEMD Buy
- REVB
- Analyst Count
- AEMD 2
- REVB 0
- Target Price
- AEMD $28.75
- REVB N/A
- AVG Volume (30 Days)
- AEMD 519.4K
- REVB 269.2K
- Earning Date
- AEMD 08-13-2025
- REVB 08-08-2025
- Dividend Yield
- AEMD N/A
- REVB N/A
- EPS Growth
- AEMD N/A
- REVB N/A
- EPS
- AEMD N/A
- REVB N/A
- Revenue
- AEMD N/A
- REVB N/A
- Revenue This Year
- AEMD N/A
- REVB N/A
- Revenue Next Year
- AEMD N/A
- REVB N/A
- P/E Ratio
- AEMD N/A
- REVB N/A
- Revenue Growth
- AEMD N/A
- REVB N/A
- 52 Week Low
- AEMD $1.10
- REVB $2.11
- 52 Week High
- AEMD $8.44
- REVB $168.00
- Technical
- Relative Strength Index (RSI)
- AEMD 42.14
- REVB 44.79
- Support Level
- AEMD $1.10
- REVB $2.97
- Resistance Level
- AEMD $1.40
- REVB $3.18
- Average True Range (ATR)
- AEMD 0.11
- REVB 0.23
- MACD
- AEMD 0.07
- REVB 0.13
- Stochastic Oscillator
- AEMD 47.92
- REVB 60.37
About AEMD Aethlon Medical Inc.
Aethlon Medical Inc is a medical therapeutic company. The company is focused on addressing unmet needs in health and biodefense. The company is focused on the development of Hemopurifier, a clinical-stage therapeutic device designed to combat cancer and eliminate life-threatening viruses from the circulatory system.
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).